Market Research Report
RNAi Technologies and Global Markets
|Published by||BCC Research||Product code||166047|
|Published||Content info||176 Pages
Delivery time: 1-2 business days
|RNAi Technologies and Global Markets|
|Published: January 18, 2016||Content info: 176 Pages||
The global market for RNA Interference technologies is expected to grow from $262.1 million in 2015 to $392.6 million in 2020, registering a compound annual growth rate (CAGR) of 8.4%.
BCC Research conducted the market assessment, the global and regional breakdown of sales data, market projection for the commercial RNAi technologies, application of the techniques in commercial sector as well as in research and development. Further, BCC Research offers the details of new developments, patent analysis, market leaders and market share, etc. for the RNAi technologies and its applications.
The report summarizes the global RNAi technologies market by category and by region. The RNAi market is analyzed based on RNAi research tools and reagents as well as on RNAi diagnostics. The research tools and reagents and therapeutics considered in this report are mainly for small/short interfering RNAs (siRNAs) and diagnostics are mainly based on microRNAs (miRNAs).
MicroRNA (miRNA) research tools, services, drug discovery etc. are excluded from this report; however, these areas are worth a separate report and thus are analyzed in BCC Research report BIO115B in detail. U.S. and non-U.S. markets are considered for the geographical market analysis. The prospective application of RNAi therapeutics in various disease classifications such as oncological, cardiovascular, neurodegenerative, ophthalmologic and others are discussed. The application and progress of RNAi technologies in agriculture is also discussed in this report.
BCC Research verified the sales data for the global and regional RNAi markets for the present and projected values through statistical analysis. The tools/technology details in the report are based on their present and their prospective application and suitability.
The study has been carried out by a team of professionals in the biotechnology industry. The project manager is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has over 14 years of industry experience. She was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S.